AI, big data and real world evidence – the challenges and opportunities
pharmaphorum
MAY 25, 2021
One of the main reasons to use RWE is to counter a common criticism of the large phase 3 trials that for so long have been the ‘gold standard’ when developing drugs and gaining authorisations from regulators. BREATHE’s Jenni Quint said that the power is not just in information from wearables but the ability to link them with other data.
Let's personalize your content